Sitagliptin (marketed as Januvia and Janumet) - acute pancreatitis
Sitagliptin (marketed as Januvia and Janumet) - acute pancreatitisAudience: Diabetes healthcare professionals, patients [Posted 09/25/2009] FDA notified healthcare professionals and patients of revisions to the prescribing information for Januvia (sitagliptin) and Janumet (sitagliptin/metformin) to include information on reported cases of acute pancreatitis in patients using these products. Eighty
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/default.htm
FDA
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
1
リリース、障害情報などのサービスのお知らせ
最新の人気エントリーの配信
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く
Pfizer HCP FS for 5-11 years of age orange cap (must dilute) 10122022
FDA Grants Accelerated Approval for Alzheimer’s Drug
Colchicine (marketed as Colcrys)
Ongoing safety review of oral osteoporosis drugs
FDA Public Health Notification: Serious Complications Associated with Transvaginal Placement of Surgical Mesh in Repair of Pelvic Organ Prolapse and Stress Urinary Incontinence
Office of Generic Drugs
Zocor (simvastatin): increased risk of muscle injury with high doses
Information for Healthcare Professionals: Cefepime (marketed as Maxipime)
HEADING 1 NO NUMBER